[Show abstract][Hide abstract] ABSTRACT: 1. We have shown previously that 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid pentyl methyl ester (MN9202), a new 1,4-dihydropyridine Ca(2+) channel modulator, has significant hypotensive effects and favourable pharmacokinetic characteristics. As a chiral molecule, MN9202 has two optical isomers. The aim of the present study was to evaluate the pharmacological properties of the two enantiomers. 2. The two enantiomers, S-(-)- and R-(+)-MN9202, were obtained by HPLC. At 1 micromol/L, both racemic MN9202 and S-(-)-MN9202 decreased the contractility of rat ventricular myocytes by 54.0 and 64.4%, respectively, compared with control, whereas R-(+)-MN9202 enhanced cell shortening by 10.1%. At 1 micromol/L, racemic MN9202 markedly reduced calcium transient (CaT) and L-type Ca(2+) channel current (I(Ca,L)) by 60.0 and 50.7%, respectively, whereas the reductions in CaT and I(Ca,L) produced by 1 micromol/L S-(-)-MN9202 were greater still (62.2 and 65.7%, respectively). In contrast, 1 micromol/L R-(+)-MN9202 increased CaT and I(Ca,L) by 11.4 and 10.6%, respectively. Furthermore, findings from kinetics studies of I(Ca,L) revealed that the steady state inactivation curve of I(Ca,L) was shifted towards a hyperpolarizing potential by S-(-)-MN9202, but towards a depolarizing potential by R-(+)-MN9202. These results demonstrate different effects of R-(+)-MN9202 and S-(-)-MN9202. 3. In conclusion, the findings of the present study suggest that the chirality of MN9202 results in opposing pharmacological properties of its two enantiomers: S-(-)-MN9202 may be responsible for the therapeutic effects of racemic MN9202, whereas R-(+)-MN9202 contributes to it unwanted effects. The findings of the present study also indicate that MN9202 may be used as a new probe with which to investigate the structure-function relationships of Ca(2+) channels.
Clinical and Experimental Pharmacology and Physiology 03/2010; 37(8):817-25. DOI:10.1111/j.1440-1681.2010.05381.x · 2.37 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The cardiac contractile function of hypertensive patients is higher than non-hypertensive patients so that it is beneficial for lowering cardiac contractile function of hypertensive patients. It remains unclear if MN9202, a dihydropyridine calcium channel blocker, has effects on positive inotropic responses induced by tetraethylammonium chloride (TEA), an antagonist of calcium-activated potassium channels, forskolin (FSK), an activator of adenylyl cyclase, isoproterenol (Iso), an activator of beta-adrenergic receptors, and methylene blue (MB), an inhibitor of guanylyl cyclase, in electrically stimulated rat cardiomyocytes. Myocyte shortening and intracellular calcium transients were assessed and the underlying mechanisms were investigated.
Twitch amplitude was measured by a video edge tracker method. Cell shortening/relengthening indexes including peak height (ph), peak height/baseline percent (ph/bl%), maximal velocity of shortening (+dL/dt), and maximal velocity of relengthening (-dL/dt) were recorded and analyzed by computer. Calcium transient amplitude (DeltaFFI) indicates intracellular calcium transients.
Iso, FSK, TEA, and MB enhanced electrical stimulation induced contraction as evidenced by increased ph, ph/bl%, +/- dL/dt, and calcium transient amplitude (DeltaFFI) compared with those in the control group. Under basal conditions, MN9202 decreased electrically induced contraction (ph, ph/bl%,+dL/dt,-dL/dt) in a concentration-dependent manner from 3 x 10(-10) to 3 x 10(-6) mol/L. MN9202 significantly decreased calcium transient amplitude. Moreover, MN9202 (3 x 10(-6) mol/L) partially but significantly blocked the positive inotropic effect induced by Iso, FSK, MB, and TEA through blocking DeltaFFI.
Iso, FSK, TEA, and MB increased the shortening and relengthening function of cardiomyocytes, which were partially blocked by MN9202. These results suggest that MN9202 may not only block the dihydropyridine receptor but may also inhibit other calcium influx. The exact mechanism of the action of MN9202 requires further study.
Archives of Medical Research 08/2008; 39(5):489-95. DOI:10.1016/j.arcmed.2008.02.010 · 2.65 Impact Factor